Several other cases of successful MEK-inhibitor use in MAP2K1-mutant malignancies have been documented, primarily non-Langerhans cell histiocytosis and hairy cell leukemia (Table 2) (30). Here, MAP2K7 is linked to Langerhans cell histiocytosis.